CEO Watchlist: Week In Review (8/3/25)

TOP NEWS AFFECTING THE STOCK MARKET THIS WEEK:

Earnings Season Week 4 Is Here: Top 5 Stocks We're Watching! (Source)

Stocks mentioned: $META, $MSFT, $PLTR, $AXON, $AMD, $OSCR, $TEM, $VST

Last week wasn’t just a win for tech, it was confirmation that the next phase of market leadership is already here. In last week’s newsletter, we forecasted a double beat from Meta Platforms (META) and Microsoft (MSFT) and both delivered. Meta’s A.I. driven ad revenue surged ahead of expectations, and Microsoft’s Azure growth validated its hybrid A.I. and cloud strategy. These weren’t just good quarters; they were a wake-up call. Tech isn’t just back. It never left. And for investors still viewing A.I. as hype rather than infrastructure, the market is quietly leaving them behind.

Looking ahead, this week’s earnings lineup may not be filled with the biggest companies in the world, but it definietly is full of some very popular ones. These are the 5 companies we're watching closely:
- Palantir Technologies (PLTR) – Quietly transforming from a defense contractor to a commercial A.I. data operating system. If they deliver strong commercial growth and margin expansion, expect re-rating higher.
- Axon Enterprise (AXON) – Not just a body cam company, its connected law enforcement cloud is a growing SaaS platform for the public sector. This stock is one of our best performers over the years, and we believe it will continue to be a strong company for many years to come. The only issue here is its valuation as it's extremely expensive! We do believe it will have a very strong earnings though and put up a double beat.
- Advanced Micro Devices (AMD) – Lagging Nvidia but still a contender in data center chips and AI acceleration. Watch data center revenue and MI300 traction. AMD is increasing the prices of their chips which will be a strong tailwind for their revenue growth moving forward. Although they don't have as strong of a software side like Nvidia does with their CUDA system, they do have very powerful chips and could rival Nvidia one day. With a market cap of only $280 billion, if they can find a way to close the gap with Nvidia, that's a lot of upside potential seeing as Nvidia is sitting at over a $4 trillion market cap today. Their past couple earnings haven't been the greatest, but we think this could be one where they put up very strong numbers. One problem is they've already ran up so much into this earnings report, the market seems to have already priced in a good earnings, and if they don't blow the numbers out of the water, we could see a pullback here.
- Oscar Health (OSCR) – Often dismissed, but has the potential to be the Stripe for healthcare insurance. Watch MLR (medical loss ratio) and guidance on scaling their tech platform business-to-business (B2B). With the way other health insurance companies have been performing, it doesn't look like the space is very attractive right now, but OSCR has been putting up phenomenal numbers lately and might just surprise investors with a good quarter.
- Nancy Pelosi's Stock Picks: Tempus AI (TEM) / Vistra (VST) – A couple of stocks are reporting this week that Nancy Pelosi personally put on the radar for retail investors. These 2 stocks include Tempus A.I. and Vistra. TEM, for those that don't know, is the latest precision medicine A.I. IPO. We view this as a higher-risk investment, but if they show revenue growth from partnerships with pharma and healthcare providers, it’s a high-upside speculative play. As for Vistra, this is a utility stock, but also a stealth A.I. energy play. VST runs one of the largest battery storage systems in Texas and is tied to compute-hungry data center expansion. We think the world is going to need a lot more energy to power A.I. moving forward, so we think Vistra will continue to have strong demand and put up solid numbers.
In today's market, valuations are rich and macro risks (especially interest rates and geopolitics) are still unresolved, but here’s the counter: we’re not betting on hope. We’re allocating to infrastructure. And when the next leg of capital flows begins, it will flow into the names building foundations, not headlines. So, we may be due for a small pullback in the overall market, as seasonality data for August and September says that these next 2 months will be relatively weak historically, but we currently believe that any significant dips are buying opportunities in this market.

Bottom line: Last week cemented that we’re still in the early innings of A.I., cloud, and robotics but the market is shifting focus from visionaries to executioners. The next wave of earnings will either validate these narratives or punish overpromisers. Stay tactical, stay selective, and don’t ignore the infrastructure stocks that may be powering the next S&P 500 leadership rotation.
World War 3 Is Back On The Table: 5 Stocks to Watch If Nuclear Tensions Explode! (Source)

Stocks mentioned: $LMT, $PLTR, $NOC, $GLD, $GDX
The U.S.–Russia–Ukraine standoff is no longer just about drones, sanctions, and aid packages. It's shifting into something far more dangerous: a revival of nuclear threats. And while most investors are still focused on earnings season or inflation data, the capital markets are beginning to quietly price in geopolitical instability as a long-term structural force. Ignore it at your own risk.

Here’s what happened: On Friday, President Donald Trump publicly announced he had ordered two nuclear submarines to be repositioned in “appropriate regions” in response to incendiary statements from Dmitry Medvedev, the former Russian president and now deputy chairman of the country’s Security Council. Medvedev had hinted at nuclear retaliation against NATO involvement in Ukraine. This was not political theater. Trump’s statement, posted online, was a direct and deliberate message for Russia. It was timed just after Russia held simulated tactical nuclear exercises and doubled down on its wartime posture. Whether or not you believe Trump’s claim is less important than this: markets are now forced to consider a future where nuclear deterrence is once again on the table.

This geopolitical flashpoint reveals a deeper macro thesis: Global defense infrastructure is becoming the new foundation of national economic security. From energy resilience to AI-driven warfare, the tools that keep the modern world safe are no longer optional, they’re investable. The core constraint is no longer military capacity, but technological readiness and supply chain control. Investors who position capital in these mission-critical areas will benefit from a wave of bipartisan and international spending that’s just beginning to accelerate.

Here are several public companies positioned to benefit from this reshaped world order:

Lockheed Martin (LMT) – Specializing in missile defense, fighter aircraft, and hypersonics, LMT is embedded in every stage of the Western deterrence strategy.

Palantir Technologies (PLTR) – Their software underpins battlefield intelligence, NATO logistics, and U.S. defense modernization. In a digital war, they’re frontline infrastructure.

Northrop Grumman (NOC) – From stealth bombers to missile systems, Northrop plays an indispensable role in American deterrence and force projection.

SPDR Gold Shares (GLD) – The go-to gold ETF, offering investors a liquid and direct hedge against geopolitical volatility, currency devaluation, and tail risk.

VanEck Gold Miners ETF (GDX) – This ETF offers exposure to top gold miners, a historically leveraged play on rising gold prices during geopolitical crises.

Yes, there’s a counterpoint: De-escalation is always possible. Diplomacy might prevail, new leadership may emerge in Russia or the U.S., and nuclear threats could remain rhetorical. But markets don’t reward wishful thinking, they reward probabilistic thinking. And right now, the probability of sustained military and energy-related spending is rising rapidly, regardless of who’s in office.

This isn’t just a war story. It’s a capital allocation story. A bifurcated world is forming, East and West, open and closed, stable and unstable, and investors must choose whether to bet on resilience. These trends won’t show up in quarterly reports just yet. But they will define the next decade. The shift is inevitable. The market hasn’t fully priced it in. That’s your edge.

These are the exact opportunities we have been able to find an edge for in the CEO Watchlist Investment Club with our club members. We actually just picked up a new purchase in the defense sector that we believe will benefit whether there is war or no war, that's just how incredible this company is. If you're an Investment Club Member, [CLICK HERE to log in] and see exactly what stock we just bought. With earnings coming out this week, we expect a lot of changes to our stock/options trading portfolios, so if you’re not a member yet, and you want to get our first insights into the market as it's happening, it is time for you to join the thousands of others who have already joined the Investment Club. We know investing can be tricky, which is exactly why we break everything down in simple terms. Whether you’re just getting started or looking to sharpen your edge, we’ll show you how we approach the market and share the specific positions we’re holding in real time. Right now, you can join the Investment Club for $200 off. You’ll get access to all of our stock purchases, our library of trading strategies, real-time stock/options trades done LIVE, and the exact system that’s helped so many members level up fast. But don’t wait [CLICK HERE to claim your spot now] before this offer expires.
Ask ChatGPT,
Stock Spotlight: This Speculative Stock Has The Potential To 10X! (Source)

Stocks mentioned: $TMDX

In a healthcare system defined by scarcity, organ transplants remain one of the most brutally constrained markets in the world. Each year, thousands of patients die not because we lack the ability to perform transplants, but because the supply chain for viable organs is broken. This isn't a logistics issue. It’s a biological one. But one company is quietly rewriting that equation. While headlines are consumed by insurance premiums and political fights over UnitedHealth ($UNH), the real story may lie in a lesser-known disruptor: TransMedics Group ($TMDX).

TransMedics builds organ care systems, portable machines that preserve, monitor, and even revitalize donor organs outside the body. Traditional transplant methods involve putting an organ on ice and racing against the clock. TMDX’s “Organ Care System” flips that paradigm by simulating real-time, body-like conditions, extending the life and viability of organs like hearts, lungs, and livers. That’s not just a technological leap, it’s a shift in market structure. More viable organs mean more transplants. And more transplants mean higher capacity utilization across the $15B+ global transplant market. For hospitals and surgical centers, this unlocks throughput. For patients, it means survival.

Why now? Because the macro is shifting. UnitedHealth ($UNH), the largest private insurer in the U.S., recently signaled a recalibration of procedure authorizations following increased regulatory scrutiny and rising procedural demand. This environment puts pressure on insurers to cut costs, but also incentivizes efficiency across care delivery systems. TransMedics directly supports this push by reducing failed transplant attempts and shortening ICU recovery times. The kicker: this is not a concept stock. TMDX just posted better-than-expected Q2 earnings, with $96.9 million in quarterly revenue, a 132% jump YoY, and raised guidance yet again! That’s the opportunity.

Of course, there’s risk. TMDX is still a small-cap, high-volatility stock in a capital-intensive space. It’s dependent on hospital adoption, regulatory tailwinds, and continued operational execution. A single recall, reimbursement change, or technology misfire could compress its margins or stall growth. But on the other hand, it has a first-mover advantage, FDA-cleared products (this is EXTREMELY hard to get approved for in this space), and expanding clinical partnerships. The longer-term upside isn’t just transplant logistics, it’s a potential monopoly over the infrastructure layer of organ transportation.

We’re still early. The market hasn’t priced in the structural shift from “cold storage” to “warm perfusion.” But healthcare systems will demand it. Governments will support it. And eventually, patients will insist on it. TransMedics isn’t a household name today, but in a world where organs can be shipped across the country and remain viable for hours longer than ever before, it may soon be impossible to ignore.

INSIDER TRADES FROM THE WEEK:

1. MSCI (MSCI) - Henry Fernandez, CEO, bought ~$6.7 million of MSCI stock between July 24-25, 2025, but it was reported to the public on July 28, 2025. (Source)

2. Charter Communications (CHTR) - Christopher Winfrey, CEO, bought ~$1 million of CHTR stock on July 31, 2025 and it was reported to the public later that same day. (Source)

3. Enterprise Products Partners (EPD) - William Montgomery, director, bought ~$500,000 worth of EPD stock on July 30, 2025 and it was reported to the public later that same day. (Source)

Over 2,000 people have already signed up for my FREE Masterclass video on how to unlock my exact strategies for finding winning stock/options trades! I'll share everything including how to find what Politicians and CEOs are buying. Don’t miss your chance to get in for FREE before spots fill up!